Literature DB >> 6684047

Intra-arterial adriamycin followed by surgery for limb sarcomas. Preliminary report.

A Azzarelli, V Quagliuolo, R A Audisio, G Bonfanti, S Andreola, L Gennari.   

Abstract

A multimodal treatment schedule for operable soft tissue sarcomas is ongoing in our institution. The main purposes are to achieve an easier radical surgery with limb preservation and to lower the risk of local relapses. Patients with documented untreated soft tissue sarcoma of the lower limb are given continuous intra-arterial regional infusion with adriamycin consecutively for 8 days up to a dose of 100 mg/m2. Radical surgery is performed by the fourth day after infusion. Preliminary data on 13 cases are available: after infusion only 6 patients presented reduction of the tumor diameters, but almost all postoperative histological examinations revealed wide areas of necrosis (up to 100%) of tumor tissue (in 9 cases greater than 50%). In 4 patients surgical treatment was completed with radiotherapy. In 2 cases the preliminary indication to disarticulation could be modified in wide excision after the postinfusional tumor reduction. The toxicity of adriamycin was typical and acceptable. Further data will be available after adequate follow-up and when more patients enter the study. These data document the feasibility of this multimodal treatment and its validity in terms of specific tumor tissue toxicity and improved surgical approach.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684047     DOI: 10.1016/0277-5379(83)90052-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  2 in total

1.  Limb-salvage procedures for osteosarcoma. An alternative to amputation.

Authors:  A C Wong; Y Akahoshi; S Takeuchi
Journal:  Int Orthop       Date:  1986       Impact factor: 3.075

2.  Toxicity of intra-arterial doxorubicin in locally advanced breast cancer.

Authors:  C J Twelves; M A Chaudary; J Reidy; M A Richards; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.